DETECTING ACUTE COGNITIVE CHANGES IN ALZHEIMERS PATIENTS

检测阿尔茨海默病患者的急性认知变化

• 批准号: 2053279
• 负责人: LAURA P. SANDS
• 金额: $ 10.23万
• 依托单位: INSTITUTE ON AGING
• 依托单位国家: 美国
• 财政年份: 1993
• 资助国家: 美国
• 起止时间: 1993-09-30 至 1998-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2053279
• 关键词: Alzheimer's disease; anticholinergic agent; brain disorder chemotherapy; cognition disorders; dementia; diphenylhydramine; drug adverse effect; human subject; interview; mental disorder diagnosis; neurotoxins; psychosis

Alzheimer's patients can experience excess disability from delirium or toxic or metabolic encephalopathies. Even though demented patients are at higher risk than intact patients for delirium and toxic or metabolic encephalopathies, the symptoms often go unrecognized. This is in part because diagnosis is confounded by the overlap in symptoms between irreversible dementia and reversible toxic or metabolic encephalopathies. One critical difference is in the clinical course; Alzheimer's disease is characterized by an insidious onset and a gradual decrement in function, while delirium and other encephalopathies can be associated with changes over shorter periods of time. What is needed to facilitate case identification is an objective method for monitoring the cognitive functioning of Alzheimer's patients. This proposal details a program of research consisting of three studies designed to investigate delirium and related disorders in Alzheimer's patients and to clarify diagnostic methods. Study I involves the application of a statistical technique to repeated assessments of cognitive functioning in Alzheimer's patients to define the normal limits of within-patient variability in cognitive performance in patients with uncomplicated Alzheimer's disease, and therefore to establish what constitutes significant changes in functioning. Study II and Study III are designed to detail the toxic effects of anticholinergic drugs commonly prescribed to Alzheimer's patients. These studies will serve to assess the validity and clinical applicability of the methods developed in Study I. The outcome of the proposed research will be the development of a clinically applicable method for monitoring AD patients that will aid in the prevention of excess disability.

阿尔茨海默氏症患者可以因ir妄或 有毒或代谢性脑病。 即使痴呆的患者处于 比完整的患者更高的风险 脑病，症状通常无法识别。 这部分是 因为诊断被症状重叠而混淆 不可逆的痴呆和可逆的有毒或代谢性脑病。 一个关键区别是临床过程。阿尔茨海默氏病是 以阴险的发作和功能逐渐降低为特征， 虽然del妄和其他脑病可能与变化有关 在较短的时间内。 促进案例需要什么 识别是监测认知的客观方法 阿尔茨海默氏症患者的功能。该建议详细介绍了一个计划 研究由三项研究组成，旨在研究del妄和 阿尔茨海默氏症患者的相关疾病并澄清诊断 方法。 研究I涉及将统计技术应用于 对阿尔茨海默氏症患者认知功能的重复评估 定义认知能力内变异性的正常限制 单纯性阿尔茨海默氏病的患者的表现， 因此确定什么构成重大变化 功能。 研究II和研究III旨在详细介绍有毒 通常针对阿尔茨海默氏症的抗胆碱能药物的作用 患者。 这些研究将有助于评估有效性和临床 研究I中开发的方法的适用性。 拟议的研究将是临床上适用的开发 监视AD患者的方法，该方法将有助于预防 多余的残疾。